Core Insights - Profusa, Inc. has entered into a collaboration with Mayo Clinic to accelerate the regulatory approval and commercialization of its Lumee™ wearable continuous tissue oxygen monitoring product [1][2] - The partnership aims to explore high-impact clinical applications for Profusa's oxygen monitoring technologies, targeting areas such as cardiovascular, renal, multi-organ, and orthopedic applications [1][2] - The Lumee technology, which has received over $100 million in investment and over a decade of development, is positioned as a first-of-its-kind platform for continuous, real-time measurement of tissue oxygen [2] Company Overview - Profusa is a commercial stage digital health company based in Berkeley, California, focused on developing tissue-integrated sensors that provide actionable, medical-grade data for personal and medical use [4] - The company aims to offer long-lasting, injectable, and affordable biosensors, along with an intelligent data platform, to deliver personalized biochemical signatures that clinicians can trust [4] Collaboration Details - The collaboration with Mayo Clinic will support the commercialization of Lumee technology for critical limb ischemia in the U.S. and aims to develop new products to expand the market and therapeutic reach of oxygen tissue monitoring technology [1][2] - Mayo Clinic's involvement includes leveraging Profusa's innovative platform to address unmet clinical challenges, particularly in monitoring beyond subcutaneous tissue [2]